MTC-1203

MTC-1203 is an experimental small-molecule inhibitor of excessive mitochondrial division being developed as a potential disease-modifying therapy for Huntington’s disease and other neurodegenerative disorders. It was originally discovered in academic research at Stanford University and is being advanced by Mitoconix Bio, which has raised venture funding to support its preclinical and early development programs.[1][3][7][9] MTC-1203 targets protein interactions that regulate mitochondrial dynamics, modulating the activity of dynamin-related protein 1 (DNM1L/Drp1) and mitochondrial fission process protein 1 (MTFP1) to prevent pathological mitochondrial fragmentation while sparing physiological fission and normal cell functions.[1][7][9] In preclinical models, the compound reduced excessive mitochondrial division and protected neurons from degeneration in Huntington’s and Parkinson’s disease models, supporting its potential as a first-in-class neuroprotective agent.[1][3][9]